Wouter B Nagengast
Overview
Explore the profile of Wouter B Nagengast including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1959
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verheij E, van Munster S, Chan M, Malekzadeh A, Cotton C, Weusten B, et al.
Gastrointest Endosc
. 2025 Feb;
PMID: 39983998
Background And Aims: Endoscopic eradication therapy (EET) for Barrett's esophagus (BE) with high-grade dysplasia (HGD) aims to prevent progression to life-limiting cancer. However, HGD patients with a short life expectancy...
2.
Vaselli M, Gabriels R, Schmidt I, Sterkenburg A, Kats-Ugurlu G, Nagengast W, et al.
Biomed Opt Express
. 2024 Oct;
15(10):5706-5722.
PMID: 39421768
Early detection of (pre)malignant esophageal lesions is critical to improve esophageal cancer morbidity and mortality rates. In patients with advanced esophageal adenocarcinoma (EAC) who undergo neoadjuvant chemoradiation therapy, the efficacy...
3.
Sikkenk D, Henskens I, van de Laar B, Burghgraef T, da Costa D, Somers I, et al.
AJR Am J Roentgenol
. 2024 Sep;
223(5):e2431440.
PMID: 39230407
CT is the standard-of-care test for preoperative locoregional staging of colon cancer (CC) but has limited diagnostic performance. More accurate preoperative staging would guide selection among expanding patient-tailored treatment options....
4.
Dijkstra B, Cordia Q, Nonnekens J, Meersma G, Donthu V, Nagengast W, et al.
J Neurosurg
. 2024 Jul;
141(6):1655-1666.
PMID: 38968617
Objective: Meningiomas are one of the most frequently occurring brain tumors and can be curatively treated with gross-total resection. A subtotal resection increases the chances of recurrence. The intraoperative identification...
5.
Schmidt I, Zhao X, van der Waaij A, Meersma G, Dijkstra F, Haveman J, et al.
Clin Cancer Res
. 2024 May;
30(15):3211-3219.
PMID: 38814263
Purpose: The ability to identify residual tumor tissues in patients with locally advanced esophageal cancer following neoadjuvant chemoradiotherapy (nCRT) is essential for monitoring the treatment response. Using the fluorescent tracer...
6.
Tenditnaya A, Gabriels R, Hooghiemstra W, Klemm U, Nagengast W, Ntziachristos V, et al.
IEEE Trans Med Imaging
. 2024 May;
43(11):3710-3718.
PMID: 38717879
Fluorescence molecular endoscopy (FME) is emerging as a "red-flag" technique with potential to deliver earlier, faster, and more personalized detection of disease in the gastrointestinal tract, including cancer, and to...
7.
Jukema J, Kusters C, Jong M, Fockens K, Boers T, van der Putten J, et al.
Gastrointest Endosc
. 2024 Apr;
100(4):616-625.e8.
PMID: 38636819
Background And Aims: Characterization of visible abnormalities in patients with Barrett's esophagus (BE) can be challenging, especially for inexperienced endoscopists. This results in suboptimal diagnostic accuracy and poor interobserver agreement....
8.
Gabriels R, van der Waaij A, Linssen M, Dobosz M, Volkmer P, Jalal S, et al.
Gut
. 2024 Apr;
73(9):1454-1463.
PMID: 38580386
Objective: Improving patient selection and development of biological therapies such as vedolizumab in IBD requires a thorough understanding of the mechanism of action and target binding, thereby providing individualised treatment...
9.
Cimen C, Bathoorn E, Loeve A, Fliss M, Berends M, Nagengast W, et al.
Antimicrob Resist Infect Control
. 2024 Mar;
13(1):31.
PMID: 38459544
Contamination of duodenoscopes is a significant concern due to the transmission of multidrug-resistant organisms (MDROs) among patients who undergo endoscopic retrograde cholangiopancreatography (ERCP), resulting in outbreaks worldwide. In July 2020,...
10.
van Munster S, Verheij E, Ozdemir O, Toes-Zoutendijk E, Lansdorp-Vogelaar I, Nieuwenhuis E, et al.
Gastroenterology
. 2024 Mar;
166(6):1058-1068.
PMID: 38447738
Background & Aims: Follow-up (FU) strategies after endoscopic eradication therapy (EET) for Barrett's neoplasia do not consider the risk of mortality from causes other than esophageal adenocarcinoma (EAC). We aimed...